SIRT6 Activation to Improve Biological Age Measured by GrimAge in Pre-frail, Middle-aged to Older Men: a Randomized Controlled Trial
Phase: NA
Conditions: Aging
Sponsor: National University of Singapore

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
1 of 24
PART I: General Information
PARTICIPANT INFORMATION SHEET
You are invited to participate in a research study. This information sheet provides you with
information about the research study. The Principal Investigator (the research doctor or the
personin charge of this research) or his/her representative will also describe this research to
you and answer all of your questions. Read the information below and ask questions about
anything you don’t understand before deciding whether or not to take part.
NUS-IRB Reference Code: NUS-IRB-2024-806
1. Protocol title
Project SIRT6 activator
2. Principal Investigator and co-investigator(s), if any, with the contact number and
address of organization
Principal Investigator:
Andrea B. Maier, MD, PhD, FRACP
Professor, NUS Academy for Healthy Longevity, Yong Loo Lin School ofMedicine, National
University of Singapore
MD11 Clinical Research Centre, #03-01, 10 Medical Drive, Singapore 117597
Contact number: (+65) 66012839
Email: a.maier@nus.edu.sg
Co-Investigators:
1. Vera Gorbunova, PhD, Professor of Biology, University of Rochester, Co-Director,
Rochester Aging Research Center
2. Christopher Chen Li-Hsian, Associate Professor, Department of Pharmacology, Yong
Loo Lin School of Medicine, National University of Singapore.
3. Dr Agnes Slater, Senior Research Fellow, NUS Academy for Healthy Longevity, Yong
Loo Lin School of Medicine, National University of Singapore.
4. Lihuan Guan, Research Fellow, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
5. Weilan Wang, PhD, is a Research Fellow at the NUS Academy for Healthy Longevity,
Yong Loo Lin School of Medicine, National University of Singapore.
6. Tay Jian Hua, PhD student, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
7. Atikah Dahiyah, Research Assistant, NUS Academy for Healthy Longevity, Yong Loo
Lin School of Medicine, National University of Singapore.
8. Anees Begam Binte Abdul Hamid, Research Assistant, NUS Academy for Healthy
Longevity, Yong Loo Lin School of Medicine, National University of Singapore.
9. Sharon Nadiyah Binte Shahul Hameed, Research Assistant, NUS Academy for
Healthy Longevity, Yong Loo Lin School of Medicine, National University of Singapore.
10. Sim Ming Ann, Associate Consultant, Anesthesia, Clinical Senior Lecturer, Yong Loo
Lin School of Medicine, National University of Singapore
11. Ellie Choi, Consultant, Division of Dermatology, Department of Medicine, National
University Hospital.
12. Christian Sotelo, Research Assistant, NUS Academy for Healthy Longevity, Yong Loo
Lin School of Medicine, National University of Singapore.
13. Mazzarine Loan Ariella Dotou is a Research Fellow at the NUS Academy for Healthy

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
2 of 24
Longevity, Yong Loo Lin School of Medicine, National University of Singapore.
14. Zhang Ding Ding, Clinic Manager, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
15. Sabarinath Nair, Research Associate, NUS Academy for Healthy Longevity, Yong Loo
Lin School of Medicine, National University of Singapore.
16. Chong Hui Min, Research Assistant, NUS Academy for Healthy Longevity, Yong Loo
Lin School of Medicine, National University of Singapore.
Renee Chng Yee Sin, Research Assistant, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
17. Shamita Venkatesh, Visiting Student, NUS Academy for Healthy Longevity, Yong Loo
Lin School of Medicine, National University of Singapore.
18. Natasha To-Anan, Research Assistant, NUS Academy for Healthy Longevity, Yong
Loo Lin School of Medicine, National University of Singapore
19. Wang Jiaqiu, Visiting Scholar, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
20. Tong Chen, Visiting Student, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
21. Chen Yong, Visiting Scholar, NUS Academy for Healthy Longevity, Yong Loo Lin
School of Medicine, National University of Singapore.
External NUS Co-Investigators:
1. Alan Graves, Chief Executive Officer of DoNotAge.org
2. Lai Hock Tan, General practitioner, Certis Group
Collaborators:
1. L’Oréal
3. Whom should I call if I have any questions or problems?
Please contact the Principal Investigator, Andrea B. Maier for all research-
related matters and in the event of research-related injuries.
Telephone: (65) 66012839/ 87142730 [Monday to Friday, 8.30 am to 5.30 pm]
Email: a.maier@nus.edu.sg;longevitytrials@nus.edu.sg
This study has undergone an ethics review by the National University of Singapore
Institutional Review Board (NUS-IRB). For an independent opinion specifically regarding
the rights and welfare of research participants, you may contact a staff member of the
National University ofSingapore Institutional Review Board at telephone (+65) 6516 1234
[Mondays to Thursdays from 8.30am to 6pm, and Fridays from 8.30am to 5.30pm, except
public holidays] or email at irb@nus.edu.sg.
4. Who can participate in the research? What is the expected duration of my
participation? What is the duration of this research?
You can participate in this study if you:
1) Are a 50-80 years old man
2) A resident of Singapore (citizenship or permanent residency is not required).
3) Have none or ONE of the following conditions that must be medication-controlled:
a) Hypertension
b) Hyperlipidemia
c) Hyperglycemia
d) Osteopenia/osteoporosis
e) Osteoarthritis

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
3 of 24
f)
Type 2 diabetes
4) Have completed the pre-screening requirements and have managed to schedule the
screening visit;
5) Agree to shave at least one day prior to each visit if you have dense facial hair on
your cheeks that may interfere with skin microbiome sampling, agree to shave at
least one day before each visit.
6) Agree to wash your skin the night before the visit and refrain from applying any facial
products in the morning before the visit for skin assessments.
7) Met the randomization criteria after the screening visit i.e., prefrail according to Fried
frailty phenotype score;
8) Are able to attend all 4 research visits for screening and research data collectionat
MD11, Yong Loo Lin School of Medicine, National University of Singapore:
screening visit, baseline visit, 3-month visit and 6-month end of intervention visit. The
screening visit will last about 1 hour, while the remaining three visits will last around
2 ~ 3 hours;
9) Willing to download study platform applications onto your mobile phone throughout the
study period (if applicable).
10) English-literate who can understand, read and write in English.
11) Without severe cognitive impairment, as determined by PI judgment.
You will NOT be able to participate in this study if you fall into the following categories:
1) Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease,
heart failure, stroke, abnormal blood clotting or bleeding disorders, peripheral vascular
disease), wound healing defects (hypertrophic scars, keloids etc.)
2) You have HIV, HEPATITIS B, HEPATITIS C*
* If you consent to undergo microbiopsy, we will take your blood sample at the
screening visit and again at Visit 3 to test for HIV, Hepatitis B, and Hepatitis C. The
cost for the test will be borne by the study team.
3) Pre-existing or history of cancer or chronic obstructive pulmonary disease (COPD)
4) You used within the 3 past weeks for more than 3 consecutive days any antibiotics or
related drugs or having planned to use these treatments during the study.
5) You have hypersensitivity or any serious reaction to local anesthesia
(lidocaine/prilocaine), local antibiotics, and antiseptics, or any other contra-indication
for skin microbiopsies.
6) Use anticoagulant medication.
7) Consume seaweed more than 3 times a week.
The duration of this research will be 6 months.
5. What is the approximate number of research subjects involved?
The study aims to recruit and randomize 60 participants into 2 equal groups (n = 30 per
group) in a double-blinded, randomized, placebo-controlled design.
6. What will be done if I take part in this research study?
If you meet the randomization criteria (prefrail according to Fried frailty phenotype score);
you will be randomized (the computer will randomly assign) into one of the 2 groups:
either to receive a Sirtuin 6 (SIRT6) activator or placebo at a dose of total 4 capsules per
day, 2 capsules in the morning and 2 capsules in the evening orally (by mouth) for a total
of 6 months in a double-blinded fashion (neither you nor the study team member will know
if you are given a SIRT6 activator or placebo).
Before you could be randomized into one of the two groups, you need to complete the
screening visit today and meet all the eligible criteria. Today, we will be collecting your
sociodemographic
data,
medical
history,
medication
records,
assess
self-reported
exhaustion
and
activity
patterns
by
a
questionnaire,
perform
anthropometric

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
4 of 24
measurements (height, weight, waist and hip circumference), physical assessments (blood
pressure
measurement,
handgrip
strength,
15
feet-timed
walking
test)
and
skin
assessments. Additionally, a maximum of 13.5 ml of blood will be collected to analyse your
health status. You will also require downloading the study platform called IQVIA. This
platform will be used to schedule your next visits, completion of study questionnaire and
reporting of any adverse events. The study platform also serves as a direct connection to
the study team.
This study will be conducted at
MD11, Yong Loo Lin School of Medicine, National
University of Singapore. All biological specimens will be obtained at MD11 and will be
processed at National University of Singapore (NUS), and all other assessments such as
anthropometric analysis, skin analysis, cardiovascular analysis, cognition test and
muscular test will be conducted at AHL.
Figure 1. Study flowchart, outlining the study visits, procedures and the timepoints.
Following your visit today, you will be informed if you are eligible to join the study based on
your frailty status. Once enrolled in the study, you will perform a series of study procedures
which are explained in detail below:
For the following 3 study visits, you will come to MD11 in the morning. You would need
to fast overnight for the blood draw as fasting blood collection is required for the study. You
have to refrain from alcohol / caffeine consumption for 24 hours and abstain from
dietary supplements. To assist you, the study team will send notification to you via the
study platform on the preparation for your appointment 14 days before your visits. We will
check whether you are feeling fine (no fever, cold, etc.) and physically fit to undergo the
procedures listed below. If you are feeling unwell, your visit will be rescheduled to
another day. You will be requested to self-declare your health status.
You will be required to donate blood samples in the four study visits. You will be in contact
with the clinic to arrange your visit schedule for your blood samples donation. You are
required to be fasting overnight before donating your blood samples. The following is the
procedure involved in the donation process:
Blood samples
Peripheral fasting blood will be drawn by a nurse/ phlebotomist/ trained SAF medic. Other

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
5 of 24
than 13.5 ml donated during the screening visit, up to 46ml of blood will be taken during
each study visits. Hence, 4 venepunctures (blood draws) will be performed within 6 months
(total blood donated: 141.5 ml).
Additionally, you will perform the following study procedures:
a) Height and weight: You will have your height and weight taken using a standard
stadiometer and a digital weight scale respectively. Your BMI will be calculated using
these values.
b) Waist/hip ratio: A staff member will perform this assessment to measure your waist
and hip circumference three times with a cloth measuring tape, at the level of the
umbilicus (waist) and at the level of the symphysis pubis and the greatest protrusion of
the gluteal muscles (hip).
c) Bioimpedance analysis: A staff member will measure your estimation of water
content; muscle mass and fat percentage will be measured using inBody 77
bioimpedance analyzer.
d) Skin assessments: You will rest for 20 minutes under conditions (temperature of
22±2°C – relative humidity between 45% ± 5%). During this period, you are required to
fill up a self-assessment questionnaire for skin and hair. It comprises of complete a
baseline self-assessment questionnaire for daily exposure, smoking habits, lifestyle,
cosmetic care habits, skin history, current conditions and hair quality. The research team
will also collect facial photos and measurements using noninvasive devices to assess
skin oiliness, hydration, elasticity, proteomics, and microbiome. You will also have the
option to take part in a microbiopsy, which involves taking a small, sample of the surface
of your skin under local anesthesia (using a numbing cream to make it painless). If you
choose not to consent to the microbiopsy, you can still participate in the study and
undergo the other assessments including the transparent adhesive discs for stratum
corneum proteomics and epigenetic analysis as well as swabs for skin microbiome.
Measurements will be done by a trained technician all along the study. All the skin
assessments included here are initiated by the collaborator L'Oreal, and the skin
analysis results will be used in the presentation to consumer panels solely for the
purpose of understanding general trends.
Additional details about the assessments are provided below, and the specific locations
on the face for each assessment are shown in Figure 2.
Figure 2. Investigational site identification on face for each assessment

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
6 of 24
Standardized facial skin imaging will be conducted with ColorFace. The research staff
will Photograph half and full faces. The colour, pigmented spots, texture, wrinkles, and
apparent age will be assessed after the study by image analysis. You are allowed to
close your eyes for the facial imaging. You will be asked whether you consent to using
your identifiable facial images for analysis and presentation to consumer panels.
Skin oiliness will be measured by a sebumeter: You will need to lie down on a bed or a
reclining chair next to the device, and your hair will be covered by a hair cap or clipped
properly. For hygiene reasons, your forehead will be wiped with a paper tissue after
each measurement. One measurement will be performed on a vertical line from the
middle of the eye and starting just above the eyebrow on each hemi forehead. Please
refer to Figure 3 below for the specific location of the sebumeter assessment.
Figure 3. Skin location (purple dot) for sebumeter assessment
Skin hydration will be measured by a corneometer: You will need to lie down on a bed or
a reclining chair next to the device, and your hair will be covered by a hair cap or clipped
properly.
The
probe
will
be
placed
perpendicularly
on
the
skin
surface,
and
measurements will be taken in less than one second. Three measurements will be taken
on each side. Please refer to Figure 4 below for the exact location of the skin
corneometer assessment.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
7 of 24
Figure 4. Skin location (3 red dots) for corneometer assessment
Skin elasticity will be measured by a cutometer: You will need to lie down on a bed or a
reclining chair next to the device, and your hair will be covered by a hair cap or clipped
properly. The instrument applies a vacuum to a small area of skin and measures the
elastic response of the skin. The probe will be kept at a 90° angle during the
measurements. The measurement will last for 4 seconds, during which there will be 1
cycle of a 2-second on (vacuum) time and a 2-second off (skin release) time. The
movement of the skin into and out of the probe will be recorded during the application
and release of suction. Please refer to Figure 5 below for the exact location used for
cutometer assessment.
Figure 5. Skin location (blue dot) for cutometer assessment
Collection of skin surface for proteomics and epigenetic analysis: The collection will be
performed using a noninvasive method, using corneodiscs (Corneofix®), a transparent
adhesive disc with a 2 cm diameter.
#1: One corneodisc will be collected until saturation by a trained technician on one zone
defined on the right side of the face under the eye and next to the nose at zone 1. This
Corneodisc will be used for proteomics analysis.
#2: Eight corneodiscs will be collected by a trained technician on the glabella area (zone
2) . They will be used for epigenetic analysis for algorithm improvement.
Please refer to Figure 6 for the exact location of the corneodisc collection.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
8 of 24
Figure 6. Zone 1 and 2 for corneodiscs collection
Collection of biological samples for microbiome analysis:
You will be asked if you have taken any antibiotics in the past 3 weeks. Skin swab for
microbiome analysis will be performed on the left side of the face on a defined area of
each subject at zone 1 and zone 3. Please refer to Figure 7 for exact location of
microbiome skin assessment.
Figure 7. Zone 1 and 2 for microbiome analysis
Microbiopsy: The microbiopsy will be performed by a trained dermatologist/certified
general practitioner after you give your consent to undergo this procedure. At least 1
hour prior to biopsy collection, a topical patch anesthetic will be applied to the
investigational zone. Local anesthesia will be given with the application of a patch
composed of two local anesthetics (lidocaine and prilocaine) acting by diffusion and
inducing skin anesthesia of a few millimeters. The patch will be applied just after the
standardized photos collection. The microbiopsy will be done on the left cheekbone.
During the sampling, you will need to lie down. After microbiopsy, the sampling zone
will be covered with bandage. Possible reactions at the biopsy site may include (but
are not limited to) subjective sensations (pain, discomfort, burning, stinging, itching),
bleeding, hematoma, skin redness, and dryness. Infection, scarring, or changes in skin

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
9 of 24
color at the biopsy site may occur. Healing takes place without stitches, reducing the
risk of residual traces left by the biopsy. Sun exposure or UV-light sessions are strictly
forbidden for 15 days after the microbiopsies collection. In case of unavoidable sun
exposure, a sunscreen with a high protection index must be applied on the face (the
product will be provided by the center). You will need to report to our study team if
there is any abnormous discomfort on the following days of the microbiopsy collection.
Post procedure, a cream would be applied to the post biopsy site to facilitate wound
healing. This would be non prescriptive and determined by the proceduralist and may
include commonly applied post procedural creams such as antiseptic gels, barrier
cream, silicon gel and sunscreen. Refer to Figure 8 below for the exact location of skin
collection for microbiopsy procedure.
Figure 8. Sampling zone (green cross) for the microbiopsy procedure
Hair fiber collection :
A trained technician will sample 1 cm2 of hair fibers from you in zone C. The root of the
hair is required as close to the scalp as possible using curved stainless-steel scissors but
without touching it (about 0.2cm from scalp).
Please refer to Figure 9 below for the location of hair collection.
Figure 9 Zone for hair collection
Only the fiber will be collected and not the bulb.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
10 of 24
The trained technician will secure the root with a clamp collar, transfer into aluminum-foil
paper, label it and place it in a labelled envelope at room temperature.
All samples will be sent to a third party for analysis at the end of the study.
e) Skin autofluorescence test: You will place your arm on the device. The device will
shine a light into your skin to measure the age of your skin. This procedure takes 10
minutes.
f)
Cognition test: You will undergo a test called RBANS (a test entails immediate
memory, visuospatial skills, attention, language and delayed memory) and this test will
take roughly 30 minutes. This test will be done in a room with a trained study team
member to ensure your comfort and privacy.
g) Muscle strength and endurance:

Handgrip strength: You will stand upright and squeeze as hard as you can on a
handgrip device, with your arm bent 90 degrees at the elbow. You will be given 3
attempts to perform your best in both hands.

8-RM Leg extension strength test: You will sit on a leg extension chair with your
back leaning against the backrest. You will perform leg extension with the initial
weights of 10 kg. If you are able to perform 8 repetitions, without being able to do
the 9th repetition, the weight will be recorded as 8-RM strength. If you are able to
do more than 8 repetitions for the given weight, weight will be added on to every
set, with a rest period of 2 mins, until 8-RM is achieved. For a validated repetition, a
complete range of motion has to be performed.
h) Cardiovascular assessment

Resting blood pressure: You will sit quietly for 5 minutes and have your blood
pressure taken by an automatic blood pressure monitor. If your blood pressure is
above 160/90 mmHg, it will be measured again after 5 minutes. If it is still
consistently above 160/90 mmHg after repeated measurements over a 30-minute
period, the site principal investigator or a physician at the Geriatric Clinic will
examine you and decide whether you should be rescheduled for another visit, or if
you will need to be withdrawn from the study.

Arterial stiffness: This measures the age of your blood vessels. You will lie
comfortably on an examination bed for 15 minutes, after which a blood pressure
cuff will be placed around your arm to measure your blood pressure. Following that,
it will be removed, and a blood pressure cuff will be placed around your thigh. The
research staff will then measure the distance from your neck to your thigh with a
measuring tape. This distance will inform us how fast your pulse travels in your
major blood vessels, which is related to how stiff the vessels are. The research
staff will then gently place a probe on your neck to detect the pulse. This procedure
will take 30 minutes.
i)
Questionnaires: You will be required to complete a few questionnaires to assess your
socio-demographic information, present and past medical information, physical activity
habits, quality of life, sleep quality, psychological status, and reproductive, skin and
hair
health.
For
most
of
these
questions,
you
may
answer
“Yes/No”.
The
questionnaires will take about 30 minutes to complete. All the questionnaires will be
provided both digitally on the study platform as well as physical copies during the study
visit.
j)
Lifestyle monitoring:

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
11 of 24

A 3-day food diary will be provided to you via the study platform, and you will then
record your routinemeals at least 3 times a week (2 weekdays and 1 weekend).
You will be reminded to complete the food diary 14 days before your scheduled
appointment via the study platform.
7. Will there be reimbursement for participation?
The study procedures will be performed at no charge to you. There is no cost for
participating in this study. However, the only direct cost incurred to you would be the
transportation cost when travelling to the study site. Thus, you
will receive a
reimbursement amount equivalent to SGD $30 per visit as a reimbursement for
transportation expenses (total of $120 upon completion of the study). You may choose to
claim the reimbursement during each visit or cumulatively at the end of the study. If you
consent to undergo a microbiopsy, you will be provided an additional $30 voucher at the
end of visit 1 and visit 3 where you undergo a microbiopsy. However, you are free to
decide at both visits if you want to consent to do the microbiopsy.
8. How will my privacy and the confidentiality of my research records be protected?
Your participation in this study will involve the collection of “Personal Data”. “Personal
Data” means data about you which makes you identifiable (i) from such data or (ii) from
that data and other information to which an organization has or is likely to have access.
This includes medical conditions, medications, investigations, and treatment history.
All research documents/databases will be devoid of participant identifiers, only the facial
image data collected will be identifiable. The participant identifiers will be kept in a source
file that is kept separate from the working data. Working data will be entered on paper
forms and electronic databases (Excel, SPSS, and IQVIA). They will then be stored in an
assigned university laptop, NUS secure cloud (NUS Dropbox Enterprise, OneDrive) and
data will be backed up to at least one encrypted external hard drive. Only the PI, co-
investigator, research coordinators and limited IQVIA staff supporting the production
platform will have access to the links to personally identifiable source data. For the
identifiable facial image data, the PI, co-investigators, research coordinators and L'Oréal
will have access to this data if the participant has consented to the use of their identifiable
data for analysis purposes. Working data may be made available to
L'Oréal who will
process the data in accordance with our written instructions. The study remains PI-
initiated and investigator-led under NUS governance, and L'Oréal is only involved in the
design of the protocol for the skin assessments and analyses for this study and their role
is limited to (e.g., providing laboratories testing support with no influence over study
outcomes).
IQVIA is a service provider with service agreement in place between AHL (NUS) and
IQVIA with clauses to protect all confidential study and other data. Access to participant
data is enabled for limited 2 IQVIA employees, who are high skilled database
administrators who are training to support platform for any enhancements, support and
operational issues. There are multiple required measures in place to secure platform and
data that includes:
o
Audit logs for all data changes
o
Access and authentication logs
o
AUL (Authorized Users List)

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
12 of 24
PART II: Information on this Human Biomedical Research
o
MFA (Multi-factored Authentication)
o
Back-up and recovery
o
Firewalls and registration based on IP for backend Admins and support team.
o
Limited authorized IQVIA support team to production environment with regular
audit on access and authentication.
To prevent unauthorized access, disclosure, or loss of data, all information collected during
the research will be secured by data encryption and passwords (for electronic data) and
under lock and key (for paper hardcopies). De-identified “research data” will be
accessible
by
the
PI, co-investigators, research
coordinators, authorized
service
providers and relevant third parties. Identifiable facial image data will be accessible by
the PI, co-investigators, research coordinators, authorized service providers and relevant
third parties only if the participant has consented to the use of their identifiable data for
analysis purpose. However, “personal data” such as participants’ contact details will only
be accessible by PI, PI-appointed research coordinators who are involved in setting up
participants’ appointments, sending reminders, and recontacting consented participants
for incidental findings and limited IQVIA staff supporting the production platform.
Additionally, if needed both “personal data” and “research data” will be made available for
inspection by authorized regulatory monitors or legal authorities, as when called for.
Information and “Personal Data” collected for this study will be kept confidential. Your
records, to the extent of the applicable laws and regulations, will not be made publicly
available. All research data collected will be kept in accordance with the National University
of Singapore’s Research Data Management Policy. Research data (without personal
identifiers) used in any publication will be kept for a minimum of 10 years before being
discarded. Where any Personal Data is collected from you, we will keep the information
confidential in accordance with the Human Biomedical Research Act and other applicable
legal rules.
However, NUS, NUS Institutional Review Board, and the Ministry of Health will be granted
direct access to your original data records to check studyprocedures and data, without
making any of your information public. By signing the Informed Consent Form attached,
you (or your legally acceptable representative, if relevant) are authorizing (i) the
collection, access to, use and storage of your “Personal Data”, and (ii) the disclosure to
authorized service providers and relevant third parties.
Data collected and entered into the Case Report Forms are the property of NUS. In the
event of any publication regarding this study, your identity will remain confidential.
Research arising in the future, based on your “Personal Data”, will be subject to review by
the relevant institutional review board.
Any biological samples and/or information containing your “Personal Data” that is collected
for the purposes described in the attached Informed Consent Form will be stored in
Singapore. Only de-identified biological samples and/or data will be transferred out of
Singapore.
All questions relating to the processing of your personal data may be directed to:
longevitytrials@nus.edu.sg.
9. What is the nature of this biomedical research?
This is a prospective 6-month double-blinded, placebo-controlled longitudinal

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
13 of 24
interventional study on prefrail, middle-aged to older (50-80 years) males to study
the effect of a SIRT6 activator supplementation on biological age. This study aims to
discover new information which may contribute to scientific and/or medical knowledge in
the nutrition and geroscience field. Treatments or interventions used in this research are
under evaluation and intended for research purposes. In this study, we intend to measure
your biological age alongside with other health indicators such as your blood tests, skin
health and physical functioning that may be related to your biological age and explore the
potential of modulating these using a SIRT6 activator supplementation.
Definition of terms used
SIRT6 activator supplementation, a polymer of L-fucose and L-fucose-4-sulfate derived
from brown
macroalgae is
available
as a dietary supplement, safe for human
consumption, and rarely causes irritation. SIRT6 activator exhibits dose-dependent
SIRT6 stimulating activity and extends lifespan in model organisms.
Chronological age is the amount of time that has passed from your birth to the given date.
It’s your age in terms of years, months, days, etc. This is the primary way people define
their age. It’s also a primary risk factor for chronic diseases, mortality, and any impairments
to bodily functions, such as hearing and memory. In contrast, biological age refers to how
old a person seems. Also known as physiologicalor functional age, biological age differs
from chronological age because it takes into consideration a number of factors other than
just the day you were born. The basic idea behind biological ageing is that ageing occurs
as you gradually accumulate damage to various cells and tissues in the body.
10. What is the purpose of this biomedical research?
The purpose of this study is to evaluate and investigate whether SIRT6 activator
supplementation can reduce biological age in middle-aged to older (50-80 years)
males. This is a 6-month double-blinded, placebo-controlled longitudinal interventional
study with the rationale to study the long-term effect of a SIRT6 activator supplementation
in healthy middle-aged adults.
The primary purpose is to study the effect of daily SIRT6 activator supplementation (2.4
g/day/6 months), compared with placebo, on DNA methylation measured using GrimAge
in prefrail, middle-aged to older (50-80 years) relatively healthy males in Singapore.
The secondary purpose is to study the effect of daily SIRT6 activator supplementation
(2.4 g/day/6 months), compared with placebo, on biological (inflammatory, glycans) and
clinical (frailty, quality of life, sleep, cognitive, body composition, muscular, cardiovascular,
reproductive and skin ageing) markers of ageing.
11. What are the possible risks, discomforts, or inconveniences to me if I participate in
this research?
There is no known side effect associated with this study procedure. While this study is
considered and rigorously planned to minimize all potential adverse events, no study is
completely risk-free. The anticipated risks to the participants are as follows:
SIRT6 activator supplementation has been declared to be safe, when taken according to
the label. Fucoidan (SIRT6 activator) use within the range of the Dietary Reference Intake
will not result in significant adverse effects, but participants may still experience side
effects, which will be documented and reported to the PI. The PI will decide whether to
withdraw the participant based on his/her clinical judgment.
Other possible risks, discomforts, or inconveniences anticipated in the procedures
involved in this study.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
14 of 24
a) Blood draw: There is some discomfort during venipuncture. There is also a risk of
bruising, but this should resolve independently over a few days.
b) Potential blood-thinning effect of fucoidan: There is a possibility for fucoidan to
have a blood-thinning effect, which could cause bleeding or prolonged wound healing.
In case it occurs, please report to the study team immediately.
c) AGE reader and colorimeter: There is minimal exposure to UV-ray on your arm.
However, the exposureis for about 12 seconds, which is less than the amount that
you would expect from standing in outdoor sunlight for a few minutes.
d) For subjects accepting to undergo the microbiopsy procedure:
There are possible risks associated with lidocaine patch application procedures and
the microbiopsy. Possible side effects associated with the lidocaine patch application
include redness, swelling, rash or other allergic reaction, and subjective sensations
(burning, stinging, tenderness). Unlikely, but serious side effects of lidocaine include
drowsiness, mental/mood changes, ringing in the ears, dizziness, vision changes,
tremors, numbness, headache, or backache. Since in this study the lidocaine is
applied using a patch (topical application) these reactions are normally not expected.
Possible reactions at the microbiopsy site may include (but are not limited to)
subjective sensations (pain, discomfort, burning, stinging, itching), bleeding, hematoma,
skin redness, and dryness. Infection, scarring, or changes in skin color at the
microbiopsy site may occur. Healing takes place without stitches, reducing the risk of
residual traces left by the microbiopsy. In case of any unforeseen circumstances, the
research team will also ensure that the PI (Andrea B Maier) or clinically trained Co-
investigators are within the vicinity of the testingsite on the study visit days.
12. What benefits can I expect from participating in the research?
There is no direct benefit from your participation. The bulk of the investigations performed
in this study are for research purposes.One benefit to the participant arising from this study
and the examinations is a report that details the results of this study procedure such as
biological age which otherwise is not a standard clinical practice. This report may be
beneficial to understand the process of ageing and discover the potential treatment. Other
potential benefits include improved ageing-related physiological and physical functions,
after a SIRT6 activator supplementation.
Research findings from this study and tests results such as BMI, blood sugar, blood lipids
and total blood count will be provided to you. These findings can be further consulted with
your treating physicians. The full report of your results will be provided only after the study
has been completed.
13. Are there any alternative procedures or treatments available to me? What are the
potential benefits and risks of such alternatives?
There are no alternative procedures or treatment available to you in this study. If you
choose not to take part in this study, you will still receive standard care for your condition,
if applicable.
14. If I am injured as a result of participating in this research, what are the compensation
and treatments available to me?
It is unlikely that you will be injured during the course of this study. If you follow the
directions of the PI/research staff in charge of this study. However, if you are injured due
to the tests conducted, NUS will pay the medical expenses for the treatment of that injury
without any legal commitment on your part to prove NUS is at fault. There are conditions
and limitations to the extent of compensation provided. You may wish to discuss this with
your PI. By signing this consent form, you will not waive any of your legal rights or release
the parties involved in this study from liability for negligence.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
15 of 24
15. Do I have to incur any expenses by participating in this research?
The study procedures will be performed at no charge to you. There are no costs for
participating in this study. The trial material (SIRT6 activator or placebo tablets) will be
provided to you free of cost.
16. What will happen to the biological material taken from me?
In this study, participants consent to the collection of biological samples (blood) for
analysis aimed at identifying biomarkers associated with biological age. Biomarkers can
include cells, molecules, enzymes, hormones, genes, and physical characteristics that
reflect normal or diseased processes in the body. Analysis may involve genetic material
and molecular testing. Leftover samples will be stored long-term by the PI for potential
future research on ageing and age-related diseases, with a minimum storage duration of
10 years.
All biological samples will be treated as donations to the study team and will not be
returned. You will not have rights to commercial gains from the research. To protect your
privacy and confidentiality, samples and research data will be de-identified, assigned
unique identifiers, and stored securely. Participants can request the PI to discard
remaining samples under specific conditions.
All biological samples and/or information containing your “Personal Data” that is collected
for the purposes described in this PIS and ICF will be stored in Singapore. Only de-
identified biological samples and/or data will be transferred out of Singapore, if required.
Biological samples transferred out of Singapore may contain genetic information for
genetic sequencing. To minimize any risk of re-identification through genetic information,
research team will secure the dataflow and restrict analysis to their accredited
laboratories only. De-identified samples will be used for future research conducted only
by NUS Healthy Longevity Translational Research Programme and its collaborators. That
might include genetic testing, such as Genome Wide Association Studies. Only de-
identified samples will be used for any future research, including genetic testing.
17. Will my participation in this research involve the use of any information that will
identify me?
Your personal data (i.e., name, date of birth and partial NRIC, contact details) will be
collected for verifying your identity and contacting you for the purpose of the study.
Additionally, your facial images may also be collected for the purposes of carrying out the
study.
18. How will my personal identifiers collected from me be kept confidential?
To prevent unauthorized access, disclosure, or loss of data, all information collected in the
course of the research will be secured by data encryption and passwords (for electronic
data) and under lock and key (for paper hardcopies). Only the PI, co-investigators,
research coordinators and limited IQVIA staff supporting the production platform will have
access to your personal data. Your identifiable facial image data will only be accessible by
the PI, co-investigators, research coordinators and L'Oréal if you have consented to
sharing of this data.
Your personal data will never be used in a publication or
presentation. To protect your confidentiality, your research data will be coded (i.e., only
identified with a code number, exception being the facial image data which remains
identifiable). All personal data (e.g., names and contact information) will be kept separate
from the research data, with the exception of the facial image data which remains
identifiable. All participating subjects will be requested to provide the contact details of a
person who can be contacted if needed, and this would be kept separate from the
research data also. The link between your personal data and the code number will bekept

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
16 of 24
confidential by the principal investigator or a trusted third party.
Your identifiable information (e.g., names, Partial IC nos.) will not be disclosed, unless
required by the applicable laws and regulations (e.g., Infectious Disease Act) or for
inspection by authorized regulatory monitors or legal authorities, as when called for.
19. Will any identifiable information obtained from me be used for future biomedical
research?
If you consent, your personal data (i.e., name, date of birth and partial NRIC) will be
retained for a period of 10 years. We may contact you for participation in future research
and/or follow-up in this study. The personal data will not be discarded upon study
completion unless specified by participants.
20. Will I be re-identified in the event of incidental finding(s) arising during the
biomedical research?
During the course of this study or future studies, there is a possibility that we might
unintentionally come to know of new information about your health condition from the blood
tests or other clinical tests that are unrelated to our research. These are called
“incidental findings”. “Incidental findings” are findings that have potential health or
reproductive importance to participants like you and are discovered in the course of
conducting the study, but are unrelated to the purposes, objectives or variables of the
study. These findings may affect your future life and/or health insurance coverage.
You will be asked to indicate whether you wish to be re-identified and notified in the case
of any important incidental finding that is related to you. The discovery of an incidental
finding, at the discretion of the University, will be communicated to you for the purpose of
seeking medical advice or treatment. In the event that you have indicated not to be re-
identified and notified, but the University has determined that the incidental finding is of
clinical significance, you may still be contacted to decide if you wish to be notified of the
incidental finding at that time.
If you agree to be re-identified and notified, your study doctor/a qualified healthcare
professional will explain the incidental finding to you and discuss and advise you on the
next steps to follow. You may wish to do more tests and seek advice to confirm this
incidental finding. The costs for any care that will be needed to diagnose or treat an
incidental finding would not be paid for by this research study. These costs would be your
responsibility.
21. Under what circumstances will I be re-contacted for further consent?
You will be re-contacted for further consent, including but not limited to changes in the
proposed research, serious adverse events that would lead to a change in the proposed
research.
22. Can I withdraw my consent to the research at any time?
Your participation in this study is completely voluntary. You may stop participating in this
study at any time without giving any reason. Your decision not to take part in this study or
to stop your participation will not affect your medical care or any benefits to which you are
entitled. If you decide to stop taking part in this study, you should inform the Principal
Investigator.
However, the data that has been collected until the time of your withdrawal will be kept and
analyzed. The reason is to enable a complete and comprehensive evaluation of the study.
The reason for the withdrawal will be requested, however you are not bound to provide a
reason for withdrawal. There will be no penalties or damages imposed on you should you

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
17 of 24
withdraw your consent to participate in this research. Once you are withdrawn from this
study,no attempt will be made to further evaluate you or to collect additional data from you.
PI of this study may stop your participation in the study at any time if they decide that it is
in your best interests. They may also do this if you do not follow the instructions required
to complete the study adequately. If you have other medicalproblems or side effects, the
doctor and/or nurse will decide if you may continue in the research study.
In the event of any new information becoming available that may be relevant to your
willingness to continue in this study, you (or your legally acceptable representative, if
relevant) will be informed in a timely manner by the PI or his/her representative.
23. Will my personal data be shared and / or processed for use in research?
Your personal data may, for the purposes of use in this study, or future research studies
after the completion of this study approved by the IRB, relevant laws and/ or the Singapore
Government (“Research Studies”), be processed into de-identified data (De-identified
Dataset). Such processing may be done by us or with the assistance of our authorized data
service providers or data intermediaries. The De-identified Dataset may be further:
a) Combined or linked with other datasets (including but not limited to Government
administrative data and research data such as Health, and health-related data, Social
data, Education data, Birth and death data, Economic and housing data, Disease
registries and databases); or
b) Shared for the purposes of the Research Studies approved by the IRB, relevant laws
and/ or the Singapore Government, with other researchers, service providers, regulators
or third parties, including:
a. Healthy Longevity Translational Research Programme, Yong Loo Lin School of
Medicine, National University of Singapore, MD11, 10, Medical Drive, 117456
Singapore
24. Will my personal data be processed overseas for use in research?
Only de-identified samples/data will be sent to external/overseas collaborators. Your data
and the research data derived from the research may be processed and transferred to
any overseas recipient. Such recipients are bound by legally enforceable obligations to
protect your personal data to a standard comparable to the data protection laws of
Singapore.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
18 of 24
PART III: Information on the Removal and Use of My Tissue(s) for this
Research
1.
What is the tissue(s) that will be taken from me and what will they be used for?
a. Blood Biomarkers
Peripheral blood will be drawn from the antecubital vein by a nurse/ phlebotomist/ trained
SAF medic. You will be requested to fast overnight, and a maximum of 46 mL of blood
will be collected into blood collection tubes in each study visits 1 - 3. This would be used to
measureclinical and biochemical parameters. The total volume of blood collection for
each participant in this study is up to 141.5 mL (13.5 mL + 41 mL + 41 mL + 46 mL).
Table 1. Breakdown of the blood tubes and their intended uses for the screening
visit.
Test(s)
Volume and type of tube(s)
Full Blood Count (FBC) and HbA1c,
1 x 3 mL anticoagulant tubes = 3 mL
Glucose fasting
1 x 2 mL sodium fluoride tube = 2 mL
Insulin, lipid panel, protein panel, liver
panel, renal panel, serology (HIV,
Hepatitis B and C)
1 x 8.5 mL plain tube (gold top) = 8.5 mL
Total
13.5 mL (3 tubes)
Table 2. Breakdown of the blood tubes and their intended uses for visits 1-2.
Test(s)
Volume and type of tube(s)
Peripheral Blood Mononuclear Cells
(PBMC)
3 x 9 mL anticoagulant tubes = 27 mL
Plasma and Buffy Coat Cells
1 x 9 mL anticoagulant tubes = 9 mL
Serum
1 x 5 mL plain tube (gold top) = 5 mL
Total
41 mL (5 tubes)
Table 3. Breakdown of the blood tubes and their intended uses for visit 3.
Test(s)
Volume and type of tube(s)
Peripheral Blood Mononuclear Cells
(PBMC)
3 x 9 mL anticoagulant tubes = 27 mL
Plasma and Buffy Coat Cells
1 x 9 mL anticoagulant tubes = 9 mL
Serum
serology (HIV, Hepatitis B and C)
1 x 5 mL plain tube (gold top) = 5 mL
1x 5 mL plain tube (gold top) = 5mL
Total
46 mL (6 tubes)
b. Skin and Hair Biomarkers
Table 3. Breakdown of the skin and hair samples and their intended uses for visits 1-3.
Sample(s)
Test
Transparent adhesive discs
Stratum corneum proteomics and
epigenetic analysis

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
19 of 24
Swabs
Skin microbiome
Hair samples
Fiber characterization
0.75mm microbiopsies
Transcriptomics, proteomic and skin
DNA methylation
2.
Will my tissue(s) be used for any purpose other than current research?
Yes, archived de-identified samples will be used for future research related to ageing
and age- related diseases
research
conducted
by
Healthy Longevity Translational
Research Programme and its collaborators (only). It might include genetic testing, such as
Genome Wide AssociationStudies. Only de-identified samples will be used for any future
research, including genetic testing.
Does this study involve the removal of human tissues from persons who lack
mental capacity or understanding and intelligence to consent to the donation of
their tissues for the study? If so, what are the proposed area(s) of research
approved by the Institutional Review Board (IRB), where the IRB has waived the
requirement that the removal of my tissue(s) be for therapeutic or diagnostic
purpose?
No, this section is not applicable as this research study only involves subjects who have
mental capacity and sufficient understanding and intelligence to consent to the donation
of their tissue(s) for research.
3.
What risks, discomforts and inconveniences will I expect if my tissue(s) is/ are
removed from me?
You may experience some pain and bruising when blood is collected from your vein.
Faintingis an occasional adverse event due to blood-taking. Appropriate first aid will be
administered should any of these events occur. Please refer to Page 13 with regards to
the potential risks and discomforts for the microbiopsy procedure.
4.
Will I still retain my rights to my tissue(s) after it has/ have been removed from me?
Donation of your tissue(s) is voluntary. By donating your tissue(s), you will relinquish your
rights to your tissue(s) and any intellectual property rights that may be derived from the use of
your tissue(s).
5.
If I am injured as a result of donating my tissue(s), what are the compensation and
treatments available to me?
If you follow the directions of the PI in charge of this research study and you are injured
during the donation of your tissue(s), the NUS will pay the medical expenses for the
treatment of that injury. By signing this consent form, you will not waive any of your legal
rights or release the parties involved in this study from liability for negligence.
Injuries sustained due to this research will be covered by the National Clinical Trials
Insurance.
6.
Do I have to incur any expenses if I donate my tissue(s) for this research?
No. You do not have to incur any expenses for donating tissues for this research.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
20 of 24
7.
Will my donated tissue(s) be used in any ways that can identify me?
Biological samples collected from the participants will be coded (de-identified) with the
same unique individual identifiers assigned to each participant. These de-identified
biological samples will be stored within the NUS and can only be accessed by qualified
laboratory personnel under the supervision of the PI or members of the study team.
Biological samples transferred out of Singapore may contain genetic information for
genetic sequencing. To minimize any risk of re-identification througeh genetic information,
research team will secure the dataflow and restrict analysis to their accredited laboratories
only. Samples will be stored until they are fully utilized or expired. Only de-identified
samples/data will be sent to external/overseas collaborators (including L’Oréal’s third-
party laboratories) who will process the samples in accordance with our written
instructions.
There may be potential use of the de-identified data and samples for future research, but
this will only apply to samples/data of participants who have consented to allow such future
usage of their samples/data.
8.
Will the records that identify me in relation to my tissue(s) donation be kept
confidential?
The PI will be responsible for the confidentiality of all study information. PI will ensure that
the
participant’s
identity
is
not
made
publicly
available.
To
maintain
subjects’
confidentiality, all case report forms/data collection forms will be devoid of personal
identifiers. Study participants will be identified only by unique identification numbers. All
physical records will be kept locked. The research database will be password-protected
and only accessible to authorized members of the study team. Linked personal data (e.g.,
name, date of birth, email address and telephone number) will be kept in a separate file
under lock and key.
9.
Will the identifiable information obtained from me in the course of tissue donation
be used for future research?
Archival de-identified samples will be used for future research conducted by the PI and
other team members in the Healthy Longevity Programme or other external collaborators.
10.
What will happen to the tissue(s) taken from me upon completion of the research?
The tissues will be stored for a minimum of 10 years, for current and future research.
11.
Will my tissue(s) be used in restricted human biomedical research?
Your tissue(s) will not be used in restricted human biomedical research involving human-
animal combinations.
12.
Will my tissue(s) be exported overseas or removed from Singapore?
De-identified samples will be used for future research conducted by the Healthy
Longevity Programme and its collaborators (only). That might include genetic testing,
such as Genome Wide Association Studies. Only de-identified samples will be used for
any futureresearch, including genetic testing. De-identified samples/data will be sent to
external/overseas collaborators (including L’Oréal’s third-party laboratories) for the

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
21 of 24
purpose of analysis for this study.
13.
Will I be re-identified in the case of incidental finding(s) arising from the use of my
tissue(s) in future research?
It is possible that during the research we may find you have pre-existing medical issues
that are unrelated to our research. These are called “incidental findings”. “Incidental
findings” are findings that have potential health or reproductive importance to participants
like you and are discovered in the course of conducting the study, but are unrelated to the
purposes, objectives or variables of the study.
You will be asked to indicate whether you wish to be re-identified and notified in the event
of an important incidental finding that is related to you. The discovery of an incidental
finding, at the discretion of the University, will be communicated to you for the purpose of
seeking medical advice or treatment. In the event that you have indicated not to be re-
identified and notified, but the University has determined that the incidental finding is of
clinical significance, you may still be contacted to decide if you wish to be notified of the
incidental finding at that time.
If you agree to be re-identified and notified, your study doctor/a qualified healthcare
professional will explain the incidental finding to you and discuss and advise you on the
next steps to follow. You may wish to do more tests and seek advice to confirm this
incidental finding. The costs for any care that will be needed to diagnose or treat an
incidental finding would not be paid for by this research study. These costs would be your
responsibility.
14.
Will I be re-contacted for further consent for the use of my tissue(s)? If so, under
what circumstances?
No, you would not be contacted for further consent for the use of tissue as consent has
been given initially.
15.
Can I withdraw my consent to the removal of my tissue(s) and/or use of my tissue(s)
in research at any time?
You can also withdraw from the research at any time without giving any reasons, by
informing the PI and all your tissue(s) collected will be discarded. However, this only
applies if the tissue is individually-identifiable and has not been used for research. Please
also note that the withdrawal of consent does not affect the research information
obtained before the consent is withdrawn and such information may still be retained and
used for research. There will be no penalties or damages imposed on you should you
withdraw your consent to participate in this research.
You are entitled to refuse to participate or discontinue participation at any time in this
research.Refusal to participate or withdrawal from participation will not affect your medical
management or cause loss of benefits to which you are otherwise entitled.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
Page 22 of 24
Consent Form for Research Subjects
Protocol title:
Project SIRT6 activator
Principal Investigator with the contact number and organization:
Andrea B. Maier, MD, PhD, FRACP
Professor, NUS Academy for Healthy Longevity, Yong Loo Lin School ofMedicine, National
University of Singapore
MD11 Clinical Research Centre, #03-01, 10 Medical Drive, Singapore 117597
Contact number: (+65) 66012839
Email: a.maier@nus.edu.sg; longevitytrials@nus.edu.sg
I hereby acknowledge that:
1. My signature is my acknowledgement that I have agreed to take part in the above research.
2. I have received a copy of this information sheet that explains the use of human biological
material / data in this research. I understand its contents and agree to donate my biological
material / data the use of this research.
3. I can withdraw from the research at any point of time by informing the Principal Investigator
although if I have donated tissue for the research, I can only withdraw my consent to use
my tissue if the tissue is individually identifiable and has not been used for research or it
is practicable to discontinue further use of my tissue for research. I am aware that that the
withdrawal of consent does not affect the research information obtained before the consent
is withdrawn and such information may still be retained and used for research.
4. I will not have any financial benefits that result from the commercial development of this
research.
5. For health information and/or human biological materials collected for use in future
research related to ageing and age-related diseases research will be conducted by the
Healthy Longevity Programme and its collaborators (which might include genetic testing),
please select 1 of the 4 choices below:
I agree to donate my coded human biological material / data collected for this research
to be used in future research. The future research will be subject to an Institutional
Review Board’s approval. OR
I agree to donate my human biological material / data collected for this research to be
used in future research. However, I would like all personal data removed from my
biological samples / data so that no one can link the samples / data to me. The future
research will be subject to an Institutional Review Board’s approval. OR
I agree to donate my human biological material / data collected for this research to be
used in future research which may include testing and development by commercial
firms. However, I would like all personal data removed from my biological samples /
data so that no one can link the samples / data to me. The future research will be
subject to an Institutional Review Board’s approval. OR
I do not agree to donate my human biological material / data collected for this research
to be used in future research. In addition, I would like to have left over biological
samples destroyed after the completion of this research.

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
Page 23 of 24
6.
For purposes of re-contact for future research, please indicate:
I agree to be re-contacted for future related studies. I understand that future studies
will be subject to an Institutional Review Board’s approval.
I do not agree to be re-contacted for future related studies. I understand that future
studies will be subject to an Institutional Review Board’s approval.
7.
For the purpose of re-contact for further consent
I agree to be re-contacted for further consent under the circumstances identified in the
Participant Information Sheet.
I do not agree to be re-contacted for further consent under the circumstances identified
in the Participant Information Sheet.
8.
For purposes of re-contact and notified in the case of an incidental finding, please indicate
I agree that I may be re-contacted and notified in the case of an incidental finding from
this research, or any other medical issue is found during the course of this study or in future
research, in order to facilitate my seeking proper medical advice. I understand that my
participation in the research is not considered medical treatment, and that the researchers
are not qualified medical practitioners able to provide diagnoses
I do not agree I may be re-contacted and notified in the case of an incidental finding
from this research, or any other medical issue is found during the course of this study or in
future research, in order to facilitate my seeking proper medical advice. I understand that
my participation in the research is not considered medical treatment, and that the
researchers are not qualified medical practitioners able to provide diagnoses
9. For the purpose of using individually identifiable facial image data, please indicate:
□
I agree that the sponsor and it’s relevant collaborators may use my individually
identifiable facial image data for the purpose of analysis and presentation to consumer
panels for assessing apparent age
□I do not agree for the sponsor and it’s relevant collaborators to use my individually
identifiable facial image data for the purpose of analysis and presentation to consumer
panels for assessing apparent age
10. For the purpose of undergoing the optional skin microbiopsy at Visit 1 and Visit 3, please
indicate:
□I agree to undergo the skin microbiopsy at Visit 1 and Visit 3
□I do not agree to undergo the skin microbiopsy at Visit 1 and Visit 3
Name (Research Participant)
Signature (Research Participant)
Date <dd-mm-yyyy>

< Project SIRT 6 activator>, Version No: 10, Date 28 February 2026
Page 24 of 24
I, the undersigned, certify to the following:
(a)
I am 21 years of age or older.
(b)
I have taken reasonable steps to ascertain the identity of the research subject.
(c)
To the best of my knowledge, the research subject had the study fully explained in a
language understood by him/ her and clearly understands the nature, risks and benefits
of his/ her participation in the study.
(d)
I have taken steps to ascertain that the consent has been given voluntarily without any
coercion or intimidation.
Name (Witness)
Signature (Witness)
Date <dd-mm-yyyy>
Note that the requirement of a witness is waived if the research is not invasive, not
interventional and is not restricted HBR. (e.g., research that comprises solely of a survey or
collection of information from research subjects)
Name (Consent Taker)
Signature (Consent Taker)
Date <dd-mm-yyyy>
The study has been explained to the research subject in
[State Language]
☐Check if this section is not applicable
Name (Translator)
Signature (Translator)
Date <dd-mm-yyyy>